{"groups":[{"description":"Participants with Relapsed/Refractory Hairy Cell Leukemia (HCL) or Hairy Cell Leukemia (HCLv)\n\nArm 1 Moxetumomab Pasudotox-tdfk + Rituximab\n\nDose escalation treatment with moxetumomab -pasudotox-tdfk and rituximab Moxetumomab pasudotox-tdfk is administered at 30 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.\n\nRituximab will be administered at 375mg/m\\^2 iv, 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.","id":"FG000","title":"Moxetumomab - Dose Escalation 30 mcg/kg"},{"description":"Dose expansion; treatment with moxetumomab -pasudotox-tdfk and Ruxience\n\nArm 1 and Arm 2 Moxetumomab Pasudotox-tdfk + Ruxience\n\nMoxetumomab pasudotox-tdfk is administered at 40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.\n\nRuxience will be administered at 375mg/m\\^2 iv, 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)","id":"FG001","title":"Moxetumomab - Dose Expansion 40 mcg/kg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}